Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers

Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia

(2016) Stine Nygaard Nielsen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The applicability of the WHO classification in paediatric AML. A NOPHO-AML study

(2015) Julie D. Sandahl et al.   BRITISH JOURNAL OF HAEMATOLOGY

Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study

(2015) Ching-Hon Pui et al.   LANCET ONCOLOGY

Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics

(2014) Lynne Lennard et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: Influence on cure rates and risk of second cancer

(2014) Mette Levinsen et al.   PEDIATRIC BLOOD & CANCER

Complying with the European Clinical Trials directive while surviving the administrative pressure – An alternative approach to toxicity registration in a cancer trial

(2013) Thomas Leth Frandsen et al.   EUROPEAN JOURNAL OF CANCER

High modal number and triple trisomies are highly correlated favorable factors in childhood B-cell precursor high hyperdiploid acute lymphoblastic leukemia treated according to the NOPHO ALL 1992/2000 protocols

(2013) K. Paulsson et al.   HAEMATOLOGICA

Second Malignant Neoplasms After Treatment of Childhood Acute Lymphoblastic Leukemia

(2013) Kjeld Schmiegelow et al.   JOURNAL OF CLINICAL ONCOLOGY

Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia

(2013) Julia A Meyer et al.   NATURE GENETICS

Risk of subsequent malignancies in survivors of childhood leukemia

(2013) Stephanie M. Perkins et al.   Journal of Cancer Survivorship

DNA repair polymorphisms influence the risk of second neoplasm after treatment of childhood acute lymphoblastic leukemia

(2012) Nina Erčulj et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia

(2012) Reid Merryman et al.   PEDIATRIC BLOOD & CANCER

Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12

(2010) Christine J. Harrison et al.   JOURNAL OF CLINICAL ONCOLOGY

Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Munster protocols

(2009) M. Stanulla et al.   BLOOD

Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study

(2009) K. Schmiegelow et al.   BLOOD

DNA Index in childhood acute lymphoblastic leukaemia: a karyotypic method to validate the flow cytometric measurement

(2009) P. RACHIERU-SOURISSEAU et al.   International Journal of Laboratory Hematology

Second Neoplasms in Survivors of Childhood Cancer: Findings From the Childhood Cancer Survivor Study Cohort

(2009) Anna T. Meadows et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral Methotrexate/6-mercaptopurine may be Superior to a Multidrug LSA2L2 Maintenance Therapy for Higher Risk Childhood Acute Lymphoblastic Leukemia

(2009) Kjeld Schmiegelow et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Lifelong Cancer Incidence in 47 697 Patients Treated for Childhood Cancer in the Nordic Countries

(2009) Jørgen H. Olsen et al.   JNCI-Journal of the National Cancer Institute

Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children's oncology group

(2009) W L Salzer et al.   LEUKEMIA

Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia

(2009) K Schmiegelow et al.   LEUKEMIA

Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study

(2008) K Schmiegelow et al.   LEUKEMIA